Astellas Pharma Inc. (ALPMY)
USD 9.53
(-0.14%)
USD 9.53
(-0.14%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1973.61 Billion JPY | 108.06% |
| 2023 | 948.56 Billion JPY | 8.77% |
| 2022 | 872.08 Billion JPY | -1.74% |
| 2021 | 887.51 Billion JPY | -13.5% |
| 2020 | 1026 Billion JPY | 60.5% |
| 2019 | 639.25 Billion JPY | 8.36% |
| 2018 | 589.91 Billion JPY | 8.79% |
| 2017 | 542.26 Billion JPY | 0.39% |
| 2016 | 540.12 Billion JPY | 13.55% |
| 2015 | 475.66 Billion JPY | 23.67% |
| 2014 | 384.63 Billion JPY | 0.29% |
| 2013 | 383.53 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1903.67 Billion JPY | 56.1% |
| 2024 Q1 | 1219.54 Billion JPY | 28.57% |
| 2024 Q4 | 1973.61 Billion JPY | 5.8% |
| 2024 FY | 1973.61 Billion JPY | 108.06% |
| 2024 Q3 | 1865.42 Billion JPY | -2.01% |
| 2023 Q3 | 943.52 Billion JPY | 1.0% |
| 2023 Q2 | 934.14 Billion JPY | -0.92% |
| 2023 Q1 | 942.79 Billion JPY | 8.11% |
| 2023 Q4 | 948.56 Billion JPY | 0.53% |
| 2023 FY | 948.56 Billion JPY | 8.77% |
| 2022 Q1 | 866.58 Billion JPY | -2.36% |
| 2022 FY | 872.08 Billion JPY | -1.74% |
| 2022 Q4 | 872.08 Billion JPY | -2.01% |
| 2022 Q2 | 843.88 Billion JPY | -2.62% |
| 2022 Q3 | 889.95 Billion JPY | 5.46% |
| 2021 FY | 887.51 Billion JPY | -13.5% |
| 2021 Q4 | 887.51 Billion JPY | -4.39% |
| 2021 Q3 | 928.23 Billion JPY | 2.3% |
| 2021 Q1 | 949.35 Billion JPY | -7.74% |
| 2021 Q2 | 907.38 Billion JPY | -4.42% |
| 2020 FY | 1026 Billion JPY | 60.5% |
| 2020 Q1 | 677.32 Billion JPY | 5.96% |
| 2020 Q2 | 683.68 Billion JPY | 0.94% |
| 2020 Q3 | 672.33 Billion JPY | -1.66% |
| 2020 Q4 | 1028.99 Billion JPY | 53.05% |
| 2019 Q2 | 604.24 Billion JPY | 2.3% |
| 2019 FY | 639.25 Billion JPY | 8.36% |
| 2019 Q4 | 639.25 Billion JPY | 0.49% |
| 2019 Q3 | 636.11 Billion JPY | 5.28% |
| 2019 Q1 | 590.63 Billion JPY | 0.12% |
| 2018 Q3 | 566.96 Billion JPY | 4.07% |
| 2018 FY | 589.91 Billion JPY | 8.79% |
| 2018 Q4 | 589.91 Billion JPY | 4.05% |
| 2018 Q2 | 544.8 Billion JPY | -6.32% |
| 2018 Q1 | 581.58 Billion JPY | 5.92% |
| 2017 Q2 | 485.92 Billion JPY | -3.41% |
| 2017 Q1 | 503.09 Billion JPY | -6.86% |
| 2017 FY | 542.26 Billion JPY | 0.39% |
| 2017 Q4 | 549.09 Billion JPY | 1.61% |
| 2017 Q3 | 540.38 Billion JPY | 11.21% |
| 2016 Q1 | 446.2 Billion JPY | -6.19% |
| 2016 Q3 | 465.5 Billion JPY | 4.0% |
| 2016 Q4 | 540.12 Billion JPY | 16.03% |
| 2016 Q2 | 447.58 Billion JPY | 0.31% |
| 2016 FY | 540.12 Billion JPY | 13.55% |
| 2015 Q2 | 420.15 Billion JPY | 8.73% |
| 2015 Q1 | 386.42 Billion JPY | 0.47% |
| 2015 FY | 475.66 Billion JPY | 23.67% |
| 2015 Q4 | 475.66 Billion JPY | -0.42% |
| 2015 Q3 | 477.66 Billion JPY | 13.69% |
| 2014 Q3 | 340.93 Billion JPY | 10.82% |
| 2014 Q1 | 317.15 Billion JPY | -17.31% |
| 2014 Q2 | 307.65 Billion JPY | -2.99% |
| 2014 FY | 384.63 Billion JPY | 0.29% |
| 2014 Q4 | 384.63 Billion JPY | 12.82% |
| 2013 Q2 | 253.26 Billion JPY | 0.0% |
| 2013 Q3 | 295.69 Billion JPY | 16.75% |
| 2013 Q4 | 383.53 Billion JPY | 29.71% |
| 2013 FY | 383.53 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | -3090.171% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | -2905.171% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | -128072.398% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -2918284.669% |
| Novartis AG | 53.19 Billion USD | -3610.153% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | -771022.973% |